2.31
+0.025(+1.10%)
Currency In USD
| Previous Close | 2.28 |
| Open | 2.26 |
| Day High | 2.34 |
| Day Low | 2.19 |
| 52-Week High | 5 |
| 52-Week Low | 1.11 |
| Volume | 1.24M |
| Average Volume | 2.36M |
| Market Cap | 613.45M |
| PE | -2.62 |
| EPS | -0.88 |
| Moving Average 50 Days | 1.73 |
| Moving Average 200 Days | 2.47 |
| Change | 0.03 |
If you invested $1000 in Autolus Therapeutics plc (AUTL) since IPO date, it would be worth $88.2 as of July 01, 2025 at a share price of $2.205. Whereas If you bought $1000 worth of Autolus Therapeutics plc (AUTL) shares 5 years ago, it would be worth $137.81 as of July 01, 2025 at a share price of $2.205.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
GlobeNewswire Inc.
Jun 12, 2025 6:00 AM GMT
Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow upMore than half of patients still in remission at 24 months38% of ongoing responders did not receive any subsequent therapy by month 33 Results sugges
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
GlobeNewswire Inc.
May 23, 2025 12:30 PM GMT
Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicityOpinion follows FDA approval and MHRA conditional marketing autho
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
GlobeNewswire Inc.
May 14, 2025 1:30 PM GMT
LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publica